PolyPeptide Group, a Swiss contract developer and manufacturer of peptide active ingredients, announced on 31 August 2026 that Samsung Peptide AG had published the prospectus for a public tender offer for the company. On 2 October it published the invitation to an extraordinary general meeting of shareholders on 26 October 2026. [1]
Separately, Neuland Laboratories in Hyderabad is commissioning a new commercial peptide manufacturing facility in 2026, the first of four planned modules in a phased expansion. [2]
Both moves sit against demand for synthetic peptide manufacturing driven by the GLP-1 class, where supply constraints during 2022–2024 shaped the compounding debate recorded elsewhere in this record. [1][2]
SOURCES
- PolyPeptide Group AG. News: Samsung Peptide AG publishes offer prospectus (31 Aug 2026); invitation to extraordinary general meeting (2 Oct 2026). Company announcement. https://www.polypeptide.com/
- Contract Pharma. Neuland Labs to add commercial peptide capacity with new India facility in 2026. 9 Mar 2026. News report. https://www.contractpharma.com/breaking-news/neuland-labs-to-add-commercial-peptide-capacity-with-new-india-facility-in-2026/
CHANGELOG · 5 Oct 2026 FIRST PUBLISHED · CORRECTIONS ARE ADDED HERE, NEVER HIDDEN